Merck

MK-3475-789

NCT03515837

JCP045

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

EGFR

Investigational

Product

Pembrolizumab (MK-3475)

Anti-PD1 antibody (i.v.)

Treatment Arms

o Experimental: Pembro+Pemetrexed+Chemo

o Active Comparator: Placebo+Pemetrexed+Chemo